Defining disease modification in myelofibrosis in the era of targeted therapy-Reference-Cited by-同舟云学术

Defining disease modification in myelofibrosis in the era of targeted therapy

Published:2022-05-02 Issue:13 Volume:128 Page:2420-2432
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Pemmaraju Naveen¹^ORCID,Verstovsek Srdan¹,Mesa Ruben²^ORCID,Gupta Vikas³,Garcia Jacqueline S.⁴,Scandura Joseph M.⁵^ORCID,Oh Stephen T.⁶,Passamonti Francesco⁷,Döhner Konstanze⁸,Mead Adam J.⁹

Affiliation:

1. Department of Leukemia University of Texas MD Anderson Cancer Center Houston Texas USA

2. UT Health San Antonio Cancer Center San Antonio Texas USA

3. Princess Margaret Cancer Centre University of Toronto Toronto Ontario Canada

4. Dana‐Farber Cancer Institute Boston Massachusetts USA

5. Department of Medicine Hematology‐Oncology Weill Cornell Medicine and the New York Presbyterian Hospital New York New York USA

6. Department of Medicine Washington University School of Medicine St. Louis Missouri USA

7. Department of Medicine and Surgery University of Insubria Varese Italy

8. Department of Internal Medicine III University Hospital Ulm Germany

9. MRC Molecular Haematology Unit MRC Weatherall Institute of Molecular Medicine, National Institute for Health Research Oxford Biomedical Research Centre, University of Oxford Oxford United Kingdom

Funder

AbbVie

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.34205

Reference82 articles.

1. Myelofibrosis in 2019: moving beyond JAK2 inhibition

2. Management of myelofibrosis after ruxolitinib failure

3. Inflammatory Microenvironment and Specific T Cells in Myeloproliferative Neoplasms: Immunopathogenesis and Novel Immunotherapies